¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Maximum Strength Midol Menstrual Caplets and Gelcaps"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • maximum urea clearance
    ÃÖ°í¿ä¼Òû¼Ò, ÃÖ°í¿ä¼Òû¼ÒÀ²
  • maximum urethral closure pressure
    ÃÖ°í¿äµµÆó¼â¾Ð
  • maximum voiding rate
    ÃÖ°í¹è´¢À²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • maximum oxygen debt
    ÃÖ´ë»ê¼ÒºÎä·®
  • maximum tolerance dose
    ÃÖ´ë³»¾à¿ë·®, ÃÖ´ë³»¾à·®, ÃÖ´ë°ßµõ¼±·®
  • maximum midexpiratory flow
    Ãִ볯¼ûÁß°£À¯·®
  • maximum acceptable daily intake
    ÀÏÀϼ·ÃëÃÖ´ëÇã¿ë·®
  • maximum allowable limit
    ÃÖ´ëÇã¿ëÇѰè
  • maximum permissible level
    ÃÖ´ëÇã¿ë¼öÁØ
  • maximum permissible limit
    ÃÖ´ëÇã¿ëÇѰè
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ¼öÁØ
  • maximum
    ÃÖ´ë
  • maximum transport
    ÃÖ´ë¿î¹ÝÄ¡, ÃÖ´ëÀ̵¿Ä¡
  • maximum allowable value
    ÃÖ´ëÇã¿ëÄ¡
  • maximum articulation score
    ÃÖ°í¸í·áµµ
  • maximum cardiac output
    ÃÖ´ë½ÉÀå¹ÚÃâ·®
  • maximum discrimination score
    ÃÖ´ë¸í·áµµ
  • maximum expiratory flow rate
    Ãִ볯¼ûÀ¯·®·ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • maximum allowable dose =MAD
    ÃÖ´ëÇã¿ë·®(¡­úÉé»åÖ).
  • maximum allowable limit
    ÃÖ´ëÇã¿ëÇѰè(¡­ùÚÍ£).
  • maximum allowable value
    ÃÖ´ëÇã¿ëÄ¡.
  • maximum articulation score
    ÃÖ°í¸í·áµµ
  • maximum breathing capacity =MBC
    ÃÖ´ëÈ£Èí(¿ë)·®(õÌÓÞû¼ýåé»åÖ), ÃÖ´ëȯ ±â
  • maximum cardiac output
    ÃÖ´ë½É¹ÚÃâ·®(õÌÓÞãýÚÑõóåÖ).
  • maximum compliance
    ÃÖ´ë¼øÀÀµµ
  • maximum discrimination score
    ÃÖ´ë¸í·áÄ¡
  • maximum dose
    ÃÖ´ë(¿ë)·®, ±Ø·®(пåÖ).
  • maximum expiratory flow rate =MEFR
    ÃÖ´ëÈ£±âÀ¯·®·ü(¡­û¼Ñ¨êüåÖëÒ).
  • maximum flow rate
    ÃÖ´ë ¿ä·ù¼Óµµ¾ç
  • maximum friction force
    Ãִ븶Âû·Â(¡­Ø¤óÍæ³).
  • maximum heart rate
    ÃÖ´ë½É¹Ú¼ö.
  • maximum intensity projection
    ÃÖ´ë°­µµ Åõ»ç
  • maximum mid-expiratory flow rate
    ÃÖ´ëÁß°£È£±â À¯Ãâ¼Óµµ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
FMP faculty mentorship program; first menstrual period; fructose monophosphate
LMP large multifunctional protease; last menstrual period; latent membrane potential; left mentoposterio...
LNMP last normal menstrual period
LRMP last regular menstrual period
MBL Marine Biological Laboratory; menstrual blood loss; minimum bactericidal level
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
MIP Maximum Intensity Projection
MLS Maximum Length Sequences
ML Maximum Likelihood
MLE Maximum Likelihood Estimate
MLE Maximum Likelihood Estimation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Hines and Brown test
    ÇÏÀνº ºê¶ó¿î ½ÃÇè
    ¾óÀ½ ¹°¿¡ ÇÑÂÊ ¼ÕÀ» ´ã±×°í Ç÷¾ÐÀÇ ¹ÝÀÀÀ» ÃøÁ¤ÇÑ´Ù °úµµ·Î Ç÷¾ÐÀÌ »ó½ÂÇϸé ÀáÀ缺 °íÇ÷¾Ð »óŸ¦ ¶æÇÑ´Ù.
  • incision and drainage
    Àý°³ ¹è³ó
    »óó, ±Ë¾ç, °øµ¿¿¡¼­ ¾×ü³ª ¹è¼³¹°À» ü°èÀûÀ¸·Î ¹èÃâ½ÃŰ´Â °Í.
  • infant and child
    ¿µÀ¯¾Æ, À¯¼Ò¾Æ
    ¿µ¾Æ±â·ÎºÎÅÍ »çÃá±â±îÁöÀÇ »ç¶÷.
  • inlay with pin and post
    À¯Á¤ Àη¹ÀÌ
    Àη¹ÀÌü¿¡ Æ÷½ºÆ® ¶Ç´Â ÇÉÀ» º´¿ëÇÏ¿© º¸Áö·ÂÀ» °­È­½ÃŲ °Í.
  • lateral and protrusive excursion
    Ãø¹æ ¹× Àü¹æ Á¢ÃË ¿îµ¿
  • lateral cord and associated anterior cornual syndrome
    Ãø»è µ¿Ãø Àü°¢ ÁõÈıº
  • maternity and infant hygiene
    ¸ð¼º ¿µ¾Æ À§»ý, ¸ð¼º ¿µ¾Æ À§»ýÇÐ
  • metal backing with pin and post
    À¯Á¤ ¼³¸éÆÇ
    ÀüÄ¡ºÎ °¡°øÄ¡ÀÇ ¼³¸é ¹× ¼Õ½ÇÃø ÀÎÁ¢¸éÀÇ ÀϺθ¦ ÇǺ¹ÇÏ´Â ¼³¸éÆÇ¿¡
  • mixed small and large cell lymphoma
    È¥ÇÕ¼º ´ë¼Ò¼¼Æ÷ ¸²ÇÁÁ¾
  • mortar and pestle
    À¯¹ß°ú À¯ºÀ
  • myoclonic epilepsy and raggedred fibers
    °£´ë ±ÙÀ° °æ·Ã¼º °£Áú
  • normocytic and normochromic anemia
    Á¤ÀûÇ÷±¸¼º ºóÇ÷
  • one : À¯±âÈ­Çп¡¼­ ÄÉÅæÀÌ ÀÖÀ½À» ³ªÅ¸³»´Â Á¢¹Ì¾î.

    one and one-half syndrome

    1°ú 1/2 ÁõÈıº
  • palm and sole system of identification
    ¼öÀå Á·Àú È®Àιý
  • perfusion and diffusion imaging
    °ü·ù È®»ê ¿µ»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
maintenance and engineering, hospital Hospital department whose primary function is the upkeep and supervision of the buildings and grounds and the maintenance of hospital physical plant and equipment which requires engineering expertise.
(12 Dec 1998)
P and P test A test formerly used by some to control anticoagulant therapy with bishydroxycoumarin and indandione drugs.
Synonym: P and P test.
(05 Mar 2000)
malignancy and immunodeficiency <radiology> High risk of malignancy (especially lymphoma/leukaemia, GI tumours): X-linked agammaglobulinaemia (Bruton's), common variable immunodeficiency, severe combined immunodeficiency (SCID kids), ataxia-telangectasia, Wiscott-Aldrich syndrome, selective IgA deficiency
(12 Dec 1998)
Papillon-Leage and Psaume syndrome <syndrome> An inherited syndrome, lethal in males, with varying combinations of defects of the oral cavity, face, and hands, including lobulated or bifid tongue, cleft or pseudocleft palate, tongue tumours, missing or malpositioned teeth, hypoplastic nasal alar cartilage, depressed nasal bridge, brachydactyly, clinodactyly, incomplete syndactyly, and, frequently, mental retardation.
There are two subtypes recognised. Type I (papillon-leage and psaume syndrome, gorlin-psaume syndrome) is inherited as an x-linked dominant trait and is found only in females and XXY males. Type II (mohr syndrome) is inherited as an autosomal recessive trait.
Inheritance: autosomal recessive and X-linked.
Synonym: OFD syndrome, orofaciodigital syndrome, Papillon-Leage and Psaume syndrome.
(05 Mar 2000)
Gell and Coombs Classification A classification system that differentiates the 4 types of hypersensitivity reactions: Type I: anaphylactic reactions, Type II: cytotoxic reactions, Type III: immune complex reactions, and Type IV: cell-mediated reactions.
(05 Mar 2000)
rate setting and review A method of examining and setting levels of payments.
(12 Dec 1998)
ratio of decayed and filled surfaces An index of decayed and filled permanent surfaces per person, per full complement of 122 tooth surfaces.
(05 Mar 2000)
ratio of decayed and filled teeth An index of decayed and filled permanent teeth per person, per full complement of 28 teeth.
(05 Mar 2000)
receptors, cytoplasmic and nuclear Proteins in the cytoplasm or nucleus that specifically bind signalling molecules and trigger changes which influence the behaviour of cells. The major groups are the steroid hormone receptors, which usually are found in the cytoplasm, and the thyroid hormone receptors, which usually are found in the nucleus. Receptors, unlike enzymes, generally do not catalyze chemical changes in their ligands.
(12 Dec 1998)
maternal age 35 and over Pregnancy in women 35 or more years of age. It is used for normal pregnancies and for problems of pregnancy occurring in a woman's late reproductive years. These include effects on the mother's physical and mental health as well as risks of perinatal mortality and foetal abnormality.
(12 Dec 1998)
VH and VL genes/domains VH and VL genes define in part the sequences of the variable heavy and light regions of immunoglobulin molecules. VH and VL domains are the regions of amino acid sequence so defined. J genes and, in the case of the heavy chain, a D gene (D=diversity) also define these regions. Gene rearrangement also plays a role in determining the sequences in which the genes are joined as the DNA of the immunoglobulin producing cell matures.
(18 Nov 1997)
referral and consultation The practice of sending a patient to another program or practitioner for services or advice which the referring source is not prepared to provide.
(12 Dec 1998)
measles, mumps and rubella vaccine A combination of live attenuated measles, mumps, and rubella viruses in an aqueous suspension; used for immunization against the respective diseases.
(05 Mar 2000)
rehabilitation of speech and language disorders Procedures for assisting a person with a speech or language disorder to communicate with maximum efficiency.
(12 Dec 1998)
patient credit and collection Accounting procedures for determining credit status and methods of obtaining payment.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cock-and-hen
    ³²³à È¥ÇÕÀÇ (Ŭ·´µî)
  • coffee-and
    Ä¿ÇÇ¿Í µµ³Ó(°¡Àå ½Ñ ½Ä»ç)
  • come-and-go
    ¿Ô´Ù°¬´ÙÇÔ;¿Õ·¡;º¯Ãµ
  • country-and-western
    ÄÁÆ®¸® ¿þ½ºÅÏ;ÄÁÆ®¸®¹ÂÁ÷(¹Ì±¹ ³²ºÎ¿¡¼­ ¹ß»ýÇÑ ¹Î¼Ó À½¾Ç)
  • cut-and-come-again
    (°í±â µîÀ»)¸î ¹øÀÌ°í º£¾î ¸Ô±â;dzºÎÇÔ;¹«ÁøÀå;¾ç¹èÃßÀÇ ÀÏÁ¾
  • cut-and-dried
    -dry()(¸».°èȹµî)¹Ì¸® ÁغñµÈ;¹Ì¸®°áÁ¤µÈ;½Å¼±ÇÔÀÌ ¾ø´Â;¹«¹Ì°ÇÁ¶ÇÑ;Ȱ±â ¾ø´Â(dull);Ʋ¿¡ ¹ÚÈù;ÁøºÎÇÑ
  • cut-and-thrust
    (°ËÀÌ)º£±â¿Í Â±â °â¿ëÀÇ
  • deaf and dumb
    ³ó¾ÆÀÇ;³ó¾ÆÀÚ(¿ë)ÀÇ
  • dribs and drabs
    ÀûÀº ¾ç
  • gin and tonic
    ÁøÅä´Ð
  • hammer and sickle
    (ÇØ¸Ó¿Í ³´À¸·Î µÈ)¼Ò·Ã ±¹±â
  • haves and havenots
    ÇÙ º¸À¯±¹°ú ºñº¸À¯±¹;(ÀϹÝÀûÀ¸·Î)°¡Áø ÀÚ(³ª¶ó)¿Í °®Áö ¸øÇÑ ÀÚ(³ª¶ó)
  • hen and chickens
    ±äº´²É(²ÜÇ®°ú);µ¢±¼°í¾Æ´ë¼ö¿°(±¤´ë³ª¹°°ú)
  • hole and corner
    ºñ¹ÐÀÇ;Â÷ÂúÀº
  • hoof and mouth disease
    =FOOT AND MOUTH DISEASE
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á